Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.09. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
22.09. | CERo Therapeutics doses third patient in AML clinical trial | 1 | Investing.com | ||
22.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort | 174 | GlobeNewswire (Europe) | Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO... ► Artikel lesen | |
09.09. | CERo Therapeutics secures key patent protection for cancer therapy | 1 | Investing.com | ||
09.09. | CERo Therapeutics sichert wichtigen US-Patentschutz für Krebstherapie | 2 | Investing.com Deutsch | ||
09.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 | 1 | GlobeNewswire (USA) | ||
08.09. | CERo Therapeutics administers second dose in AML clinical trial | 1 | Investing.com | ||
08.09. | CERo Therapeutics verabreicht zweite Dosis in klinischer AML-Studie | 2 | Investing.com Deutsch | ||
08.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia | 74 | GlobeNewswire (Europe) | Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE... ► Artikel lesen | |
05.09. | CERo Therapeutics Stock Drops 13% Despite FDA Fast Track For Lead AML Therapy | 1 | RTTNews | ||
05.09. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) | 171 | GlobeNewswire (Europe) | Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program SOUTH SAN FRANSCISCO... ► Artikel lesen | |
04.09. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
22.08. | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
15.08. | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
31.07. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 | 144 | GlobeNewswire (Europe) | Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif.... ► Artikel lesen | |
28.07. | CERO THERAPEUTICS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
21.07. | Cero Therapeutics registers up to 12.5M shares for potential sale under equity agreement with Keystone | 1 | Seeking Alpha | ||
21.07. | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
18.07. | Cero Therapeutics schließt weitere Tranche der Serie-D-Finanzierung ab | 9 | Investing.com Deutsch | ||
18.07. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,470 | +0,71 % | ROUNDUP/Aktien Frankfurt Eröffnung: Moderate Verluste - Richtungssuche | FRANKFURT (dpa-AFX) - Nach den leichten Gewinnen vom Vortag haben die Anleger am deutschen Aktienmarkt am Donnerstag wieder etwas auf die Bremse getreten. "Die Richtungssuche geht weiter", konstatierte... ► Artikel lesen | |
EVOTEC | 6,612 | +4,36 % | Von Abnehmspritzen bis Krebstherapie: Diese Plattform-Technologie greift gleich mehrere Milliardenmärkte an! | Anzeige / WerbungDie moderne Medizin steht vor einer gewaltigen Aufgabe: Immer mehr Menschen leiden an sogenannten Wohlstandserkrankungen wie Adipositas, Diabetes, Multiple Sklerose oder MASH, der gefürchteten... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
BIONTECH | 89,10 | -0,11 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,870 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
IMMUNOVANT | 16,735 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
VALNEVA | 4,940 | +0,12 % | Valneva: Chikungunya-Impfstoff zeigt über vier Jahre stabile Wirksamkeit | Valneva hat neue Daten zur Antikörperpersistenz seines Chikungunya-Impfstoffs IXCHIQ veröffentlicht. Vier Jahre nach einer einmaligen Impfung zeigten nach Angaben des Biotech-Unternehmens vom Dienstag... ► Artikel lesen | |
MODERNA | 23,345 | -3,21 % | Moderna-Aktie: Kurs heute im Minus (21,2677 €) | Am US-amerikanischen Aktienmarkt liegt die Aktie von Moderna zur Stunde im Minus. Der jüngste Kurs betrug 24,79 US-Dollar. Eine Verbilligung in Höhe von 1,09 US-Dollar müssen derzeit die Aktionäre von... ► Artikel lesen | |
PRIME MEDICINE | 6,675 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 19,050 | -0,10 % | S&P Dow Jones Indices: Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 | NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and... ► Artikel lesen | |
89BIO | 14,830 | +0,95 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,180 | +2,74 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |